These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7728268)

  • 21. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
    Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D
    Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Managing of platelet transfusion refractoriness of haematological malignancies. Experience IPC-EFSAM].
    Dettori I; Ladaique P
    Transfus Clin Biol; 2014 Nov; 21(4-5):207-9. PubMed ID: 25267204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of idiopathic myelofibrosis with alloimmunization to HLA-identical platelet transfusions not responsive to antibody absorption over protein-A columns.
    Menicucci A; Di Pietro G; Venturini S; Avanzi G
    Transfus Sci; 1995 Dec; 16(4):391-5. PubMed ID: 10159510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Resuscitation necessitated by a transfusion reaction after HLA mismatched platelets substitution].
    Kuntz BM; Schöttler B; Brüster HT
    Beitr Infusionsther Transfusionsmed; 1994; 32():307-9. PubMed ID: 9480114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
    Waterman HR; Kapp LM; Munday A; Odem-Davis K; Zimring JC
    Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of HLA antibody formation in patients with hemato-oncologic diseases by using leukocyte depleted blood preparations].
    Adamzik ID; Jin J; Sachs V; Thomsen H
    Infusionsther Transfusionsmed; 1995 Feb; 22(1):9-13. PubMed ID: 7727966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention and circumvention of refractoriness to platelet transfusions: interface between preparative and therapeutic apheresis.
    Beris P; Dornier C
    Curr Stud Hematol Blood Transfus; 1990; (57):267-76. PubMed ID: 2272206
    [No Abstract]   [Full Text] [Related]  

  • 30. [Transfusion of platelet concentrates].
    Rieux C; Lee K; Lavaud A; Bierling P
    Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet transfusion and HLA immunisation.
    Sirchia G
    Vox Sang; 1986; 51(1):74. PubMed ID: 3739327
    [No Abstract]   [Full Text] [Related]  

  • 32. [Refractoriness to platelet transfusion].
    Tsurumi H; Hara T; Moriwaki H
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):332-4. PubMed ID: 9833505
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelets as immunogens.
    Waters AH
    Vox Sang; 1994; 67 Suppl 3():125-7. PubMed ID: 7975474
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
    Stanworth SJ; Navarrete C; Estcourt L; Marsh J
    Br J Haematol; 2015 Nov; 171(3):297-305. PubMed ID: 26194869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions.
    Heddle NM; Blajchman MA
    Blood; 1995 Feb; 85(3):603-6. PubMed ID: 7833464
    [No Abstract]   [Full Text] [Related]  

  • 36. Can we "terminate" alloimmune platelet transfusion refractoriness?
    Vassallo RR; Norris PJ
    Transfusion; 2016 Jan; 56(1):19-22. PubMed ID: 26756708
    [No Abstract]   [Full Text] [Related]  

  • 37. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and management of platelet transfusion refractoriness.
    Novotny VM
    Vox Sang; 1999; 76(1):1-13. PubMed ID: 9933848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
    Toor AA; Choo SY; Little JA
    Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.